Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
VEmbND0fBxvXzfst
Listen
